Skip to main content
Erschienen in: Endocrine 2/2024

18.08.2023 | Original Article

Lateral lymph node metastasis in papillary thyroid microcarcinoma: a study of 5241 follow-up patients

verfasst von: Jiaying Ruan, Zhendong Chen, Shitu Chen, Zehang Xu, Liping Wen, Zhuochao Mao, Jiejie Shen, Jian Liu, Weibin Wang

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the impact of lateral lymph node metastasis in papillary thyroid microcarcinoma (PTMC).

Methods

5241 PTMC patients with follow-up information were enrolled in the current study. These patients underwent primary surgery in our situation from January 1997 to December 2016. Additionally, a validation cohort consisting of 274 PTMC patients who underwent primary surgery between January 2020 and December 2021 was also included. Univariable and multivariate logistic analyses were conducted to identify the association between clinicopathologic features and lateral lymph node metastasis (LLNM). Kaplan–Meier survival curve analysis was used to calculate the disease-free survival (DFS) rate. The fitting curve was generated to identify the quantitative relationship between central lymph node metastases (CLNM) and LLNM.

Results

Of 5241 PTMC patients, cervical lymph node metastasis was detected in 1494 (28.5%) cases, including 1364 (26.0%) with CLNM only and 130 (2.5%) with LLNM. With a median follow-up time of 60 months (interquartile range [IQR], 44–81), recurrence was detected in 114 patients (2.2%). Multivariate Cox regression analyses showed that LNM was the only independent risk factor for recurrence, with HR values of 3.03 in CLNM and 11.14 in LLNM, respectively. Tumor diameter >0.5 cm (hazard ratio [HR]:1.80), multifocality (HR:2.59), bilaterality (HR:2.13), extrathyroidal invasion (HR:2.13), and CLNM (HR:5.11) were independent risk factors for LLNM. The prevalence of LLNM escalated significantly with increasing number of lymph node involvement in CLNM when stratified by the number of metastatic lymph nodes and trend was observed similarly in the validation cohort. The fitting curve showed that the incidence of LLNM could be as high as 20.7% when the number of CLNM ≥ 5.

Conclusions

By analyzing a large database with follow-up information, our study provides evidence that LLNM is significantly correlated with tumor recurrence in patients with PTMC. Tumor size (>0.5 cm), multifocality, bilaterality, extrathyroidal extension (ETE) and CLNM are independent risk factors for LLNM.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat S. Hundahl, I. Fleming, A. Fremgen et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995 [see comments]. Cancer 83(12), 2638–2648 (1998)CrossRefPubMed S. Hundahl, I. Fleming, A. Fremgen et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995 [see comments]. Cancer 83(12), 2638–2648 (1998)CrossRefPubMed
2.
Zurück zum Zitat G. Pellegriti, F. Frasca, C. Regalbuto et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J. Cancer Epidemiol. 2013, 965212 (2013) G. Pellegriti, F. Frasca, C. Regalbuto et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J. Cancer Epidemiol. 2013, 965212 (2013)
3.
Zurück zum Zitat F.C. Liu, H.T. Lin, S.F. Lin et al. Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer [J]. Oncotarget 8(45), 78429–78451 (2017)CrossRefPubMedPubMedCentral F.C. Liu, H.T. Lin, S.F. Lin et al. Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer [J]. Oncotarget 8(45), 78429–78451 (2017)CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat C. Hedinger, W. Williams, L H Sobin. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 63(5), 908–911 (1989) C. Hedinger, W. Williams, L H Sobin. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 63(5), 908–911 (1989)
5.
Zurück zum Zitat S. Leboulleux, R. Tuttle, F. Pacini et al. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 4(11), 933–942 (2016) S. Leboulleux, R. Tuttle, F. Pacini et al. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 4(11), 933–942 (2016)
6.
Zurück zum Zitat F. Pisello, G. Geraci, C. Lo Nigro et al. Neck node dissection in thyroid cancer. A review. G Chir. 31(3), 112–118 (2010)PubMed F. Pisello, G. Geraci, C. Lo Nigro et al. Neck node dissection in thyroid cancer. A review. G Chir. 31(3), 112–118 (2010)PubMed
7.
Zurück zum Zitat K.T. Robbins, A.R. Shaha, J.E. Medina et al. Consensus statement on the classification and terminology of neck dissection. Arch. Otolaryngol. Head. Neck Surg. 134(5), 536–538 (2008)CrossRefPubMed K.T. Robbins, A.R. Shaha, J.E. Medina et al. Consensus statement on the classification and terminology of neck dissection. Arch. Otolaryngol. Head. Neck Surg. 134(5), 536–538 (2008)CrossRefPubMed
8.
Zurück zum Zitat I. Rosen, A. Azadian, P. Walfish et al. Ultrasound-guided fine-needle aspiration biopsy in the management of thyroid disease. Am. Surg. 166(4), 346–349 (1993) I. Rosen, A. Azadian, P. Walfish et al. Ultrasound-guided fine-needle aspiration biopsy in the management of thyroid disease. Am. Surg. 166(4), 346–349 (1993)
9.
Zurück zum Zitat N. Wada, Q. Duh, K. Sugino, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann. Surg. 237(3), 399–407 (2003) N. Wada, Q. Duh, K. Sugino, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann. Surg. 237(3), 399–407 (2003)
10.
Zurück zum Zitat Y. Xu, L. Xu, J. Wang. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. J Surg Res. 221, 128–134 (2018) Y. Xu, L. Xu, J. Wang. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. J Surg Res. 221, 128–134 (2018)
11.
Zurück zum Zitat D. Lin, N. Qu, R. Shi et al. Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma. OncoTargets Ther. 9, 5307–5316 (2016) D. Lin, N. Qu, R. Shi et al. Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma. OncoTargets Ther. 9, 5307–5316 (2016)
12.
Zurück zum Zitat I. Hay, C. Grant, J. Van Heerden et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112(6) 1139–1146 (1992) I. Hay, C. Grant, J. Van Heerden et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112(6) 1139–1146 (1992)
13.
Zurück zum Zitat E.L. Mazzaferri, Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr. Pr. 6(6), 469–476 (2000)CrossRef E.L. Mazzaferri, Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr. Pr. 6(6), 469–476 (2000)CrossRef
14.
Zurück zum Zitat Y. Ito, T. Jikuzono, T. Higashiyama et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg. 30(10), 1821–1828 (2006) Y. Ito, T. Jikuzono, T. Higashiyama et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg. 30(10), 1821–1828 (2006)
15.
Zurück zum Zitat B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)CrossRefPubMedPubMedCentral B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat W. Liu, W. Cao, Z. Dong et al. Can active surveillance management be developed for patients with low-risk papillary thyroid microcarcinoma? A preliminary investigation in a Chinese population. Endocr. Pr. 28(4), 391–397 (2022)CrossRef W. Liu, W. Cao, Z. Dong et al. Can active surveillance management be developed for patients with low-risk papillary thyroid microcarcinoma? A preliminary investigation in a Chinese population. Endocr. Pr. 28(4), 391–397 (2022)CrossRef
17.
Zurück zum Zitat S.J. Cho, C.H. Suh, J.H. Baek et al. Active surveillance for small papillary thyroid cancer: a systematic review and meta-analysis. Thyroid 29(10), 1399–1408 (2019)CrossRefPubMed S.J. Cho, C.H. Suh, J.H. Baek et al. Active surveillance for small papillary thyroid cancer: a systematic review and meta-analysis. Thyroid 29(10), 1399–1408 (2019)CrossRefPubMed
18.
Zurück zum Zitat K. Horiguchi, Y. Yoshida, K. Iwaku et al. Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults. Endocr. J. 68(7), 763–780 (2021)CrossRefPubMed K. Horiguchi, Y. Yoshida, K. Iwaku et al. Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults. Endocr. J. 68(7), 763–780 (2021)CrossRefPubMed
19.
Zurück zum Zitat E. Molinaro, M.C. Campopiano, R. Elisei, Management of endocrine disease: papillary thyroid microcarcinoma: toward an active surveillance strategy. Eur. J. Endocrinol. 185(1), R23–r34 (2021)CrossRefPubMed E. Molinaro, M.C. Campopiano, R. Elisei, Management of endocrine disease: papillary thyroid microcarcinoma: toward an active surveillance strategy. Eur. J. Endocrinol. 185(1), R23–r34 (2021)CrossRefPubMed
20.
Zurück zum Zitat A. Miyauchi, Y. Ito, H. Oda. Insights into the management of papillary microcarcinoma of the thyroid. Thyroid, 28(1), 23–31 (2018) A. Miyauchi, Y. Ito, H. Oda. Insights into the management of papillary microcarcinoma of the thyroid. Thyroid, 28(1), 23–31 (2018)
21.
Zurück zum Zitat L. Zhang, W. Wei, Q. Ji, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J. Clin. Endocrinol. Metab. 97(4), 1250–1257 (2012) L. Zhang, W. Wei, Q. Ji, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J. Clin. Endocrinol. Metab. 97(4), 1250–1257 (2012)
22.
Zurück zum Zitat J. Kwak, E. Kim, M. Kim, et al. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Medicine 16(5), 1348–1355 (2009) J. Kwak, E. Kim, M. Kim, et al. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Medicine 16(5), 1348–1355 (2009)
23.
Zurück zum Zitat S. Siddiqui, M. White, T. Antic, et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid. 26(6), 807–815 (2016) S. Siddiqui, M. White, T. Antic, et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid. 26(6), 807–815 (2016)
24.
Zurück zum Zitat National Health Commission of the People’s Republic of China. Thyroid Cancer Diagnosis and Treatment Guidelines [J]. Chinese Archives of General Surgery (Electronic Edition), 13(01), 1–15 (2019) National Health Commission of the People’s Republic of China. Thyroid Cancer Diagnosis and Treatment Guidelines [J]. Chinese Archives of General Surgery (Electronic Edition), 13(01), 1–15 (2019)
25.
Zurück zum Zitat Z.Y. Rui, Y. Liu, W. Zheng et al. A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis. Clin. Exp. Med. 21(2), 277–286 (2021)CrossRefPubMed Z.Y. Rui, Y. Liu, W. Zheng et al. A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis. Clin. Exp. Med. 21(2), 277–286 (2021)CrossRefPubMed
26.
Zurück zum Zitat W. Wang, X. Su, K. He et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients. Cancer 122(2), 198–206 (2016)CrossRefPubMed W. Wang, X. Su, K. He et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients. Cancer 122(2), 198–206 (2016)CrossRefPubMed
27.
Zurück zum Zitat Z. Chen, J. Ruan, Y. Yao et al. A comparison of the Seventh and Eighth Editions of the AJCC staging systems to predict recurrence in papillary thyroid microcarcinoma. Ann. Surg. Oncol. 28(11), 6564–6571 (2021)CrossRefPubMed Z. Chen, J. Ruan, Y. Yao et al. A comparison of the Seventh and Eighth Editions of the AJCC staging systems to predict recurrence in papillary thyroid microcarcinoma. Ann. Surg. Oncol. 28(11), 6564–6571 (2021)CrossRefPubMed
28.
Zurück zum Zitat Z. Lu, J. Sheng, Y. Zhang et al. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. J. Pathol. 239(1), 72–83 (2016) Z. Lu, J. Sheng, Y. Zhang et al. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. J. Pathol. 239(1), 72–83 (2016)
29.
Zurück zum Zitat W. Wang, H. Wang, X. Teng et al. Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Hum. Pathol. 41(9), 1299–1309 (2010)CrossRefPubMed W. Wang, H. Wang, X. Teng et al. Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Hum. Pathol. 41(9), 1299–1309 (2010)CrossRefPubMed
30.
Zurück zum Zitat K. Joseph, S. Edirimanne, G. Eslick. Multifocality as a prognostic factor in thyroid cancer: a meta-analysis. Int. J. Surg. 50, 121–125 (2018) K. Joseph, S. Edirimanne, G. Eslick. Multifocality as a prognostic factor in thyroid cancer: a meta-analysis. Int. J. Surg. 50, 121–125 (2018)
31.
Zurück zum Zitat J.Y. Kwak, E.K. Kim, M.J. Kim et al. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann. Surg. Oncol. 16(5), 1348–1355 (2009)CrossRefPubMed J.Y. Kwak, E.K. Kim, M.J. Kim et al. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann. Surg. Oncol. 16(5), 1348–1355 (2009)CrossRefPubMed
32.
Zurück zum Zitat S. Zhan, D. Luo, W. Ge et al. Clinicopathological predictors of occult lateral neck lymph node metastasis in papillary thyroid cancer: a meta-analysis. Head Neck 41(7), 2441–2449 (2019) S. Zhan, D. Luo, W. Ge et al. Clinicopathological predictors of occult lateral neck lymph node metastasis in papillary thyroid cancer: a meta-analysis. Head Neck 41(7), 2441–2449 (2019)
33.
Zurück zum Zitat K. Kim, X. Zheng, J.K. Kim et al. The contributing factors for lateral neck lymph node metastasis in papillary thyroid microcarcinoma (PTMC). Endocrine 69(1), 149–156 (2020)CrossRefPubMed K. Kim, X. Zheng, J.K. Kim et al. The contributing factors for lateral neck lymph node metastasis in papillary thyroid microcarcinoma (PTMC). Endocrine 69(1), 149–156 (2020)CrossRefPubMed
34.
Zurück zum Zitat J.W. Feng, J. Ye, L.Z. Hong et al. Nomograms for the prediction of lateral lymph node metastasis in papillary thyroid carcinoma: stratification by size. Front Oncol. 12, 944414 (2022)CrossRefPubMedPubMedCentral J.W. Feng, J. Ye, L.Z. Hong et al. Nomograms for the prediction of lateral lymph node metastasis in papillary thyroid carcinoma: stratification by size. Front Oncol. 12, 944414 (2022)CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Y.K. So, M.J. Kim, S. Kim et al. Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location. Int J. Surg. 50, 94–103 (2018)CrossRefPubMed Y.K. So, M.J. Kim, S. Kim et al. Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location. Int J. Surg. 50, 94–103 (2018)CrossRefPubMed
Metadaten
Titel
Lateral lymph node metastasis in papillary thyroid microcarcinoma: a study of 5241 follow-up patients
verfasst von
Jiaying Ruan
Zhendong Chen
Shitu Chen
Zehang Xu
Liping Wen
Zhuochao Mao
Jiejie Shen
Jian Liu
Weibin Wang
Publikationsdatum
18.08.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03486-5

Weitere Artikel der Ausgabe 2/2024

Endocrine 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.